ERBB2 and non-small cell lung carcinoma: More favourable data were reported in phase II studies evaluating antibody-drug conjugates (ADC) ado-trastuzumab emtansine and trastuzumab deruxtecan in HER2-mutated NSCLC patients [11, 12].